• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alimera Sciences

Alimera Sciences wins Health Canada nod for diabetic macular edema implant

December 5, 2018 By Sarah Faulkner

Alimera Scienes updated logo

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien device is a sustained release implant that delivers fluocinolone acetonide and is indicated to treat diabetic macular edema in people who have been previously given corticosteroids and did not have a […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

pSivida licenses European rights for Durasert to Alimera

July 11, 2017 By Sarah Faulkner

pSivida

pSivida (NSDQ:PSDV) said today that it restructured a deal with Alimera Sciences (NSDQ:ALIM) to grant Alimera rights to the Durasert three-year treatment for posterior segment uveitis in Europe, the Middle East and Africa. Alimera, which holds an exclusive license to pSivida’s intravitreal implant, Iluvien, plans to apply for a secondary indication for Iluvien for posterior segment uveitis. […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, pSivida Corp.

Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant

March 13, 2017 By Sarah Faulkner

Alimera Sciences (NSDQ:ALIM) said today that it inked an exclusive distribution deal with Spain-based Brill Pharma for its Iluvien sustained-release intravitreal implant. According to the agreement, Brill Pharma will promote, market and commercialize the diabetic macular edema implant in Spain. It will also negotiate with the Spanish Ministry of Health on the implant’s public price and […]

Filed Under: Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: Alimera Sciences, Brill Pharma, Knight Therapeutics

Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

February 22, 2017 By Sarah Faulkner

Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

Alimera Sciences (NSDQ:ALIM) and Knight Therapeutics (TSE:GUD) said today that Health Canada accepted the companies’ New Drug Application for its intravitreal implant, Iluvien. The FDA approved Atlanta-based Alimera’s sustained release intravitreal implant in 2014 to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise in […]

Filed Under: Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

Alimera surges on buyout rumors

December 17, 2015 By Brad Perriello

(Reuters) — Alimera Sciences (NSDQ:ALIM), an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter. The company has reached out to investment banks to seek advice on how it would be valued in a potential sale and who the likely buyers would be, […]

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, pSivida Corp.

Alimera raises $37.5M in private placement

February 18, 2014 By drugdelivery

Alimera raises $37.5M in private placement

Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences

Alimera's Iluvien vision repair implant wins national insurance coverage in France

July 25, 2013 By drugdelivery

pSivida
Alimera Sciences

The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, Insurance, pSivida Corp.

pSivida launches Phase III study of its micro-sized eye implant

July 5, 2013 By drugdelivery

pSivida launches Phase III of its drug/device combo for vision loss r

pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, Clinical Trials, pSivida Corp.

pSivida wins approval for Iluvien in Germany

May 27, 2013 By drugdelivery

pSividaAlimera

pSivida‘s (NSDQ:PSDV) announced that it won German approval for its Iluvien drug-device combination, launching immediately and touting the 1st commercial treatment this month in Deutschland on a patient with diabetic macular edema.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, pSivida Corp.

pSivida's new Iluvien approval attempt focuses on safety

April 2, 2013 By drugdelivery

pSivida

Alimera Sciences

Filed Under: Drug-Device Combinations, Preclinical Trials Tagged With: Alimera Sciences, pSivida Corp.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS